Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dexcom Inc (NQ: DXCM )

70.48 -1.32 (-1.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dexcom Inc

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DexCom
From Faruqi & Faruqi LLP
Via GlobeNewswire
Is It Time to Buy July's Worst-Performing S&P 500 Stocks?
These stocks took a dive recently, and that could spell opportunity. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
S&P 500, Nasdaq 100 Snap 8-Day Winning Streak: What Triggered Wall Street's Setback On Tuesday?
S&P 500 ended Tuesday's session with slight declines, halting its best winning streak since May 2024. Here's the latest. 
Via Benzinga
Topics Stocks
Exposures US Equities
S&P 500, Nasdaq Look To Snap Best Win Streaks Of 2024
Stocks are taking a breather, with the S&P 500 Index and Nasdaq Composite Index firmly lower this afternoon after yesterday nabbing their eighth-straight gains and best win streaks of the year. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Helen of Troy, Owens & Minor, Iris Energy, and DexCom and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
S&P 500, Nasdaq 100 Extend 8-Session Winning Streak As Wall Street Jitters 'Go Poof': Monday's Key Stock Movers
Via Benzinga
Topics Stocks
Exposures US Equities
2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200
These companies' growth paths should only be briefly interrupted by headwinds. 
Via The Motley Fool
2 Growth Stocks to Buy at a Discount
Look beyond share price at the business behind the stock, and you might find there's more for investors to consider. 
Via The Motley Fool
Large-Cap Stocks In Trouble: Here Are The 10 Worst Performers
Over the past twelve months, 10 large-cap stocks have underperformed all others. Here’s this week’s list of the top 10 worst performing large-caps. 
Via Talk Markets
S&P 500, Nasdaq 100 Mark Seventh Straight Positive Session, Strongest Week Since October 2023: Friday's Top Movers
S&P 500 and Nasdaq 100 indices gain for seventh straight day, marking best weekly performance since October 2023 on positive economic data. SPY and QQQ close with modest daily gains while DIA has best... 
Via Benzinga
Topics Stocks
Exposures US Equities
1 Growth Stock Down 43% to Buy Right Now
Here's why DexCom should be on your radar after the company's share price plunged recently. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Top 3 Stocks to Watch: Options Traders Bet on Big Gains
Three stocks have stood out for call option traders to bet on in the coming months as a view for a recovery rally after an S&P 500 sell-off last week 
Via MarketBeat
Topics Stocks
Exposures US Equities
Should You Buy the 3 Worst Nasdaq 100 Stocks Since the Tech Sector Selloff?
The tech sector began selling off in July as investors abandoned former higher fliers, leaving these three as the worst Nasdaq 100 stocks. 
Via InvestorPlace
DexCom, Inc. (DXCM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Should You Buy DexCom Stock After Its Post-Earnings Sell-Off?
DexCom now trades at a drastically lower earnings multiple than it has in the past. 
Via The Motley Fool
Jim Cramer: This Energy Stock Is A Buy, Stay Away From DexCom
The "Mad Money" host says Dexcom had "a real bad miss... they still really haven't fully explained why that is." 
Via Benzinga
These Stocks Just Dropped by 40% and 15% -- Should You Buy the Dip?
It might be a great time to buy low. 
Via The Motley Fool
Chips, Glorious Chips!
Someone's gotta make 'em, and someone's gotta buy 'em. 
Via The Motley Fool
Is It Time to Buy July's Worst-Performing Nasdaq Stocks?
These three Nasdaq stocks saw price drops of more than 35% last month. Are they good buys or too risky to touch today? 
Via The Motley Fool
Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
Hims & Hers stock is showing the market why its fair value is double-digits above where it trades today, with Wall Street analysts to agree 
Via MarketBeat
Topics Bonds ETFs
Exposures Debt Markets
Down 40% in 1 Day, Is DexCom Stock Still a Buy?
Competition and new growth headwinds could derail the stock even further. 
Via The Motley Fool
Bragar Eagel & Squire, P.C. Is Investigating Nano Nuclear, Iris Energy, Ford, and DexCom and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of DexCom, Inc. (DXCM) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio?
Top 10 stocks with highest gains last week, including Exact Sciences, Alnylam Pharmaceuticals, Resmed, Coca-Cola Consolidated, DexCom, Sprouts Farmers Market, UL Solutions, Labcorp Holdings, C.H.... 
Via Benzinga
Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Hims & Hers stock is looking like a worthy dip to watch in the coming months, especially as its decline had nothing to do with company operations 
Via MarketBeat
The Law Offices of Frank R. Cruz Announces Investigation of DexCom, Inc. (DXCM) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of DexCom, Inc. (DXCM) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
As Diabetes Battle Heats Up, Spotlight Turns To Dexcom, Abbott
Dexcom is taking on bigger rival Abbott Laboratories with a continuous glucose monitor for non insulin users. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.